Redox-Responsive Polycondensate Neoepitope for Enhanced Personalized Cancer...

Paper

Abstract

A versatile and highly effective platform remains a major challenge in the development of personalized cancer vaccines. Here, we devised a redox-responsive polycondensate neoepitope (PNE) through a reversible polycondensation reaction of peptide neoantigens and adjuvants together with a tracelessly responsive linker-monomer. Peptide-based neoantigens with diverse sequences and structures could be copolymerized with molecular adjuvants to form PNEs of high loading capacity for vaccine delivery without adding any carriers. The redox-responsive PNEs with controlled molecular weights and sizes efficiently targeted and accumulated in draining lymph nodes and greatly promoted the antigen capture and cross-presentation by professional antigen presenting cells. Mice immunized with PNEs showed markedly enhanced antigen-specific T cell response and the protective immunity against the tumor cell challenge.

Analysis

Paper intelligence

Summary

This paper introduces a novel redox-responsive polycondensate neoepitope (PNE) platform for personalized cancer vaccines that enhances immune response without carriers.

Key findings

PNEs can copolymerize peptide neoantigens and adjuvants with high loading capacity.
Redox-responsive PNEs efficiently target draining lymph nodes.
PNEs promote antigen capture and cross-presentation by antigen-presenting cells.
Mice immunized with PNEs showed enhanced antigen-specific T cell response and tumor protection.

Methods

Reversible polycondensation reaction of peptide neoantigens and adjuvants.
Use of a tracelessly responsive linker-monomer.
Copolymerization of peptide-based neoantigens with molecular adjuvants.
Immunization of mice with PNEs.
Tumor cell challenge in immunized mice.

Limitations

The abstract does not explicitly state limitations of the PNE platform.

Applications

Development of enhanced personalized cancer vaccines.

Confidence100%

Discovery

Related papers

2026Crossref0 citations

Evaluation of Computational Neoantigen Prioritization Strategies for Personalized Cancer Vaccines

Vladimir Zyrin; Evgeniy Mozheiko; Ivan Valiev; Alexey Lazarev; Tigran Gevorkyan; Matvey Murashko; Konstantin Okonechnikov

Sep 28, 2026Vaccines

2026Crossref0 citations

First mRNA‑based flu vaccine wins US approval, Moderna’s Ebola candidate reaches the clinic, and early‑phase cancer vaccine trials broaden across personalized and off‑the‑shelf platforms

Ashling Cannon

Sep 10, 2026Vaccine Insights

2026arXiv

Optimizing RNA yield using deep neural networks coupled to massively parallel screening

Dinghai Zheng; Justin Hong; Jun Wang; Adrien Villain; Mickaël Costallat; Fernando Ulloa Montoya; Vikram Agarwal

Aug 24, 2026

2026Crossref0 citations

Artificial intelligence in peptide cancer vaccine design: from neoantigen discovery to immunogenicity prediction

Petar Brlek; Jan Kolić; Luka Bulić; Vedrana Škaro; Dragan Primorac

Jul 29, 2026Frontiers in Genetics

2026Crossref0 citations

Neoantigen-Encoded Oncolytic Viruses as Personalized Cancer Vaccines

Almohanad A. Alkayyal

Feb 26, 2026Pharmaceuticals

2026PubMed

Longer-term response to SARS-CoV-2 vaccination after allogeneic blood stem cell transplantation.

Crodel CC; Gork L; Göpel W; Linke P; Sinn K; Miethke J; Hochhaus A; Hilgendorf I

Jan 1, 2026Journal of cancer research and clinical oncology

Source record

Publication metadata

Authors: Lixia Wei; Yu Zhao; Xiaomeng Hu; Li Tang
Published: Feb 3, 2020
Journal or venue: ACS Central Science
DOI: 10.1021/acscentsci.9b01174
Paper type: journal article
Source: Openalex

DOI OpenAlex